Logo image of ATRA

ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis

NASDAQ:ATRA - Nasdaq - US0465132068 - Common Stock - Currency: USD

7.82  +0.26 (+3.44%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ATRA. ATRA was compared to 567 industry peers in the Biotechnology industry. ATRA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ATRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ATRA has reported negative net income.
ATRA had a negative operating cash flow in the past year.
ATRA had negative earnings in each of the past 5 years.
In the past 5 years ATRA always reported negative operating cash flow.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

ATRA's Return On Assets of -78.28% is on the low side compared to the rest of the industry. ATRA is outperformed by 68.90% of its industry peers.
Industry RankSector Rank
ROA -78.28%
ROE N/A
ROIC N/A
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

With an excellent Gross Margin value of 83.71%, ATRA belongs to the best of the industry, outperforming 86.57% of the companies in the same industry.
ATRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

ATRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ATRA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ATRA has been reduced compared to 5 years ago.
ATRA has a worse debt/assets ratio than last year.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -28.19, we must say that ATRA is in the distress zone and has some risk of bankruptcy.
ATRA has a worse Altman-Z score (-28.19) than 89.58% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.19
ROIC/WACCN/A
WACC8.16%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 0.48 indicates that ATRA may have some problems paying its short term obligations.
ATRA has a worse Current ratio (0.48) than 93.29% of its industry peers.
ATRA has a Quick Ratio of 0.48. This is a bad value and indicates that ATRA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ATRA (0.40) is worse than 93.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.48
Quick Ratio 0.4
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.20%, which is quite impressive.
Looking at the last year, ATRA shows a very strong growth in Revenue. The Revenue has grown by 1402.45%.
ATRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 85.07% yearly.
EPS 1Y (TTM)80.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.5%
Revenue 1Y (TTM)1402.45%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%670.3%

3.2 Future

ATRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.28% yearly.
Based on estimates for the next years, ATRA will show a decrease in Revenue. The Revenue will decrease by -0.92% on average per year.
EPS Next Y60.52%
EPS Next 2Y31.25%
EPS Next 3Y18.1%
EPS Next 5Y18.28%
Revenue Next Year-70.2%
Revenue Next 2Y-47.57%
Revenue Next 3Y-40.72%
Revenue Next 5Y-0.92%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

A more expensive valuation may be justified as ATRA's earnings are expected to grow with 18.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.25%
EPS Next 3Y18.1%

More info and screens

0

5. Dividend

5.1 Amount

ATRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (5/2/2025, 8:00:01 PM)

7.82

+0.26 (+3.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-07 2025-03-07/amc
Earnings (Next)05-07 2025-05-07
Inst Owners51.62%
Inst Owner Change0%
Ins Owners2.56%
Ins Owner Change0.28%
Market Cap46.61M
Analysts80
Price Target15.64 (100%)
Short Float %14.65%
Short Ratio11.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.37%
Min EPS beat(2)-48.64%
Max EPS beat(2)67.38%
EPS beat(4)2
Avg EPS beat(4)-15.94%
Min EPS beat(4)-94.51%
Max EPS beat(4)67.38%
EPS beat(8)4
Avg EPS beat(8)-19.34%
EPS beat(12)6
Avg EPS beat(12)-9.67%
EPS beat(16)8
Avg EPS beat(16)-8.7%
Revenue beat(2)2
Avg Revenue beat(2)39.87%
Min Revenue beat(2)12.04%
Max Revenue beat(2)67.7%
Revenue beat(4)3
Avg Revenue beat(4)14.64%
Min Revenue beat(4)-29.79%
Max Revenue beat(4)67.7%
Revenue beat(8)3
Avg Revenue beat(8)-29.06%
Revenue beat(12)5
Avg Revenue beat(12)28.04%
Revenue beat(16)7
Avg Revenue beat(16)25.53%
PT rev (1m)15.72%
PT rev (3m)-6.12%
EPS NQ rev (1m)8.44%
EPS NQ rev (3m)-395.47%
EPS NY rev (1m)4.29%
EPS NY rev (3m)5.98%
Revenue NQ rev (1m)33.33%
Revenue NQ rev (3m)-85.83%
Revenue NY rev (1m)-57.64%
Revenue NY rev (3m)-64.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.97
EYN/A
EPS(NY)-5.12
Fwd EYN/A
FCF(TTM)-11.77
FCFYN/A
OCF(TTM)-11.73
OCFYN/A
SpS22
BVpS-16.6
TBVpS-16.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.71%
FCFM N/A
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.87%
Cap/Sales 0.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.48
Quick Ratio 0.4
Altman-Z -28.19
F-Score4
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.5%
EPS Next Y60.52%
EPS Next 2Y31.25%
EPS Next 3Y18.1%
EPS Next 5Y18.28%
Revenue 1Y (TTM)1402.45%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%670.3%
Revenue Next Year-70.2%
Revenue Next 2Y-47.57%
Revenue Next 3Y-40.72%
Revenue Next 5Y-0.92%
EBIT growth 1Y70.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.45%
EBIT Next 3Y12.47%
EBIT Next 5Y-3.99%
FCF growth 1Y64.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.39%
OCF growth 3YN/A
OCF growth 5YN/A